Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• "Moderate Buy" consensus from 15 analysts (13 buys, 1 hold, 1 sell) with a one‑year average target of $38, though several brokers have trimmed their price targets recently.
• Viridian reported a Q4 EPS loss of $1.08 and revenue of $0.13M (versus $15.75M expected), carries deeply negative margins and analysts forecast roughly -$4.03 EPS for the year, while the stock trades near $13.96 with a $1.43B market cap.
• Amgen's positive Phase 3 results for a competing thyroid eye disease program have driven investor selling, unusual put activity and a drop to nine‑month lows, increasing near‑term commercial and clinical risk for VRDN.

Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the fifteen research firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $38.00.

Several research analysts have commented on VRDN shares. Wells Fargo & Company dropped their price objective on shares of Viridian Therapeutics from $29.00 to $20.00 and set an "equal weight" rating for the company in a research note on Tuesday, March 31st. Evercore reissued an "outperform" rating and set a $44.00 target price on shares of Viridian Therapeutics in a research note on Tuesday, January 20th. The Goldman Sachs Group lowered their target price on shares of Viridian Therapeutics from $36.00 to $31.00 and set a "buy" rating for the company in a research note on Tuesday. Needham & Company LLC lowered their target price on shares of Viridian Therapeutics from $42.00 to $32.00 and set a "buy" rating for the company in a research note on Monday, March 30th. Finally, UBS Group assumed coverage on shares of Viridian Therapeutics in a research note on Wednesday, January 7th. They set a "buy" rating and a $50.00 target price for the company.

Viridian Therapeutics Stock Up 0.4%

NASDAQ VRDN opened at $13.96 on Wednesday. The company has a quick ratio of 12.65, a current ratio of 12.65 and a debt-to-equity ratio of 0.08. The company has a fifty day moving average of $27.58 and a two-hundred day moving average of $27.82. The firm has a market capitalization of $1.43 billion, a price-to-earnings ratio of -4.24 and a beta of 1.16. Viridian Therapeutics has a 52 week low of $9.90 and a 52 week high of $34.29.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.18). The firm had revenue of $0.13 million for the quarter, compared to analysts' expectations of $15.75 million. Viridian Therapeutics had a negative return on equity of 83.25% and a negative net margin of 483.57%. On average, analysts predict that Viridian Therapeutics will post -4.03 earnings per share for the current year.

Institutional Trading of Viridian Therapeutics

A number of large investors have recently made changes to their positions in the stock. Avoro Capital Advisors LLC purchased a new stake in shares of Viridian Therapeutics during the fourth quarter valued at $46,680,000. Seven Fleet Capital Management LP purchased a new stake in shares of Viridian Therapeutics during the fourth quarter valued at $456,000. Virtu Financial LLC purchased a new stake in shares of Viridian Therapeutics during the fourth quarter valued at $531,000. Invesco Ltd. boosted its stake in shares of Viridian Therapeutics by 127.1% during the fourth quarter. Invesco Ltd. now owns 183,468 shares of the company's stock valued at $5,710,000 after purchasing an additional 102,676 shares during the period. Finally, XTX Topco Ltd purchased a new stake in shares of Viridian Therapeutics during the fourth quarter valued at $1,464,000.

Key Viridian Therapeutics News

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: Goldman Sachs cut its price target from $36 to $31 but kept a "buy" rating, implying substantial upside versus the current price and signaling continued analyst conviction. Benzinga
• Positive Sentiment: Royal Bank of Canada lowered its target from $42 to $30 but retained an "outperform" rating, again indicating analysts still see long‑term value despite near‑term headwinds. Benzinga
• Neutral Sentiment: Coverage roundup: a Globe & Mail piece groups Viridian with other healthcare names and summarizes recent analyst commentary — useful context but no new company‑specific catalyst. Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN) and Bristol-Myers Squibb (BMY)
• Negative Sentiment: Competitive clinical risk: Amgen reported positive Phase 3 results for a thyroid eye disease program (TEPEZZA OBI trial reported a 77% proptosis response), which investors view as direct competition to Viridian’s lead program and has been cited as a main reason for recent selling pressure. Why Is Viridian Therapeutics Stock Sinking Monday?
• Negative Sentiment: Press coverage highlights the Amgen link as the driver of the drop, increasing investor concern about VRDN’s addressable market and near‑term commercial prospects. Viridian Therapeutics Stock Is Tanking. Why the Drop Is Linked to This Amgen Study.
• Negative Sentiment: Sentiment/flow signal: unusual options activity — ~7,501 put contracts purchased (a large multiple of typical volume) — indicating hedging or speculative bearish bets that can accelerate downside moves in volatile sessions.
• Negative Sentiment: MSN and other outlets note VRDN has fallen to 9‑month lows amid the Amgen developments, underscoring the short‑term negative narrative investors are reacting to. VRDN stock falls to 9-month lows – what’s the Amgen connection?

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc NASDAQ: VRDN is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company's lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.